Bengt Hallberg

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8154067/publications.pdf

Version: 2024-02-01

44	3,214	236925	265206
papers	citations	25 h-index	42 g-index

45	45	45	3875
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nature Reviews Cancer, 2013, 13, 685-700.	28.4	538
2	Anaplastic lymphoma kinase: signalling in development and disease. Biochemical Journal, 2009, 420, 345-361.	3.7	375
3	The activation of phosphatidylinositol 3-kinase by Ras. Current Biology, 1994, 4, 798-806.	3.9	303
4	The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma. Cancer Cell, 2012, 22, 117-130.	16.8	270
5	Calcium/calmodulin inhibition of basic-helix-loop-helix transcription factor domains. Nature, 1994, 368, 760-764.	27.8	165
6	Jeb signals through the Alk receptor tyrosine kinase to drive visceral muscle fusion. Nature, 2003, 425, 512-516.	27.8	151
7	Characterization of the expression of the ALK receptor tyrosine kinase in mice. Gene Expression Patterns, 2006, 6, 448-461.	0.8	142
8	FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase. ELife, 2015, 4, e09811.	6.0	123
9	Appearance of the Novel Activating F1174S ALK Mutation in Neuroblastoma Correlates with Aggressive Tumor Progression and Unresponsiveness to Therapy. Cancer Research, 2011, 71, 98-105.	0.9	80
10	The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma. Science Signaling, 2014, 7, ra102.	3.6	80
11	Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684. Biochemical Journal, 2011, 440, 405-414.	3.7	77
12	The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN. DMM Disease Models and Mechanisms, 2016, 9, 941-52.	2.4	62
13	Cell culture andDrosophilamodel systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma. DMM Disease Models and Mechanisms, 2013, 6, 373-82.	2.4	59
14	Targeting anaplastic lymphoma kinase in neuroblastoma. Apmis, 2019, 127, 288-302.	2.0	53
15	Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells,Drosophilaand mice. Oncotarget, 2016, 7, 29011-29022.	1.8	51
16	Exoenzyme T of Pseudomonas aeruginosa elicits cytotoxicity without interfering with Ras signal transduction. Cellular Microbiology, 2001, 3, 237-246.	2.1	49
17	Nerve growth factor induced stimulation of Ras requires Trk interaction with Shc but does not involve phosphoinositide 3-OH kinase. Oncogene, 1998, 17, 691-697.	5.9	48
18	Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib. Journal of Physical Education and Sports Management, 2018, 4, a002550.	1.2	47

#	Article	IF	Citations
19	Intragenic anaplastic lymphoma kinase (ALK) rearrangements: Translocations as a novel mechanism of ALK activation in neuroblastoma tumors. Genes Chromosomes and Cancer, 2015, 54, 99-109.	2.8	45
20	MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)â€“addicted neuroblastomas. Science Signaling, 2017, 10, .	3.6	41
21	Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways. Science Signaling, 2018, 11, .	3.6	36
22	Phosphoproteomic analysis of anaplastic lymphoma kinase (<scp>ALK</scp>) downstream signaling pathways identifies signal transducer and activator of transcriptionÂ3 as a functional target of activated <scp>ALK</scp> in neuroblastoma cells. FEBS Journal, 2013, 280, 5269-5282.	4.7	35
23	ALK ligand ALKAL2 potentiates MYCNâ€driven neuroblastoma in the absence of ALK mutation. EMBO Journal, 2021, 40, e105784.	7.8	35
24	The ligand Jelly Belly (Jeb) activates theDrosophilaAlk RTK to drive PC12 cell differentiation, but is unable to activate theMouseALK RTK. Journal of Experimental Zoology Part B: Molecular and Developmental Evolution, 2007, 308B, 269-282.	1.3	32
25	14-3-3 proteins are required for the inhibition of Ras by exoenzyme S. Biochemical Journal, 2000, 349, 697-701.	3.7	30
26	Internalization and Down-Regulation of the ALK Receptor in Neuroblastoma Cell Lines upon Monoclonal Antibodies Treatment. PLoS ONE, 2012, 7, e33581.	2.5	27
27	11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in Neuroblastoma. Cell Reports, 2020, 32, 108171.	6.4	25
28	Targeted Disruption of ALK Reveals a Potential Role in Hypogonadotropic Hypogonadism. PLoS ONE, 2015, 10, e0123542.	2.5	24
29	Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells. Frontiers in Oncology, 2019, 9, 579.	2.8	24
30	ALK and NSCLC: Targeted therapy with ALK inhibitors. F1000 Medicine Reports, 2011, 3, 21.	2.9	23
31	ATR inhibition enables complete tumour regression in ALK-driven NB mouse models. Nature Communications, 2021, 12, 6813.	12.8	21
32	The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness. Scientific Reports, 2020, 10, 218.	3.3	20
33	Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells. Scientific Reports, 2019, 9, 19353.	3.3	19
34	Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUGÎ±) in neuroblastoma patient samples with chromosome arm 2p rearrangements. Genes Chromosomes and Cancer, 2020, 59, 50-57.	2.8	18
35	Novel Mechanisms of ALK Activation Revealed by Analysis of the Y1278S Neuroblastoma Mutation. Cancers, 2017, 9, 149.	3.7	17
36	Anaplastic lymphoma kinase L1198F and G1201E mutations identified in anaplastic thyroid cancer patients are not ligand-independent. Oncotarget, 2017, 8, 11566-11578.	1.8	16

#	Article	IF	Citations
37	Chromosome Imbalances in Neuroblastomaâ€"Recent Molecular Insight into Chromosome 1p-deletion, 2p-gain, and 11q-deletion Identifies New Friends and Foes for the Future. Cancers, 2021, 13, 5897.	3.7	13
38	Extracellular domain shedding of the ALK receptor mediates neuroblastoma cell migration. Cell Reports, 2021, 36, 109363.	6.4	9
39	BioID-Screening Identifies PEAK1 and SHP2 as Components of the ALK Proximitome in Neuroblastoma Cells. Journal of Molecular Biology, 2021, 433, 167158.	4.2	9
40	Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma With Chromosomal 2p Gain and Anaplastic Lymphoma Kinase and Tropomyosin Receptor Kinase Activation. JCO Precision Oncology, 2022, 6, e2100271.	3.0	8
41	Loss of RET Promotes Mesenchymal Identity in Neuroblastoma Cells. Cancers, 2021, 13, 1909.	3.7	6
42	Neuroblastoma xenograft models demonstrate the therapeutic potential of 177Lu-octreotate. BMC Cancer, 2021, 21, 950.	2.6	4
43	The ALK Receptor Family. , 2015, , 1-51.		0
44	11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in Neuroblastoma. SSRN Electronic Journal, 0, , .	0.4	0